Practical Guidelines for the Treatment of Gestational Trophoblastic Disease: Collaboration of the European Organisation for the Treatment of Trophoblastic Disease (EOTTD)–European Society of Gynaecologic Oncology (ESGO)–Gynecologic Cancer InterGroup (GCIG)–International Society for the Study of Trophoblastic Diseases (ISSTD)
Abstract
Gestational trophoblastic diseases (GTDs) are a group of pregnancy-related premalignant and malignant diseases with generally a favorable prognosis when treated adequately. Many different treatment protocols exist worldwide. To our knowledge, this is the first set of global consensus-based guidelines for GTD. Four international organizations (European Organisation for the Treatment of Trophoblastic Diseases, European Society of Gynecologic Oncology, Gynecologic Cancer Intergroup, and International Society for the Study of Trophoblastic Diseases) delegated 53 expert GTD clinicians from 31 countries who formulated nine consensus-based definitions and the minimum criteria required to be a GTD center. Furthermore, 18 flow diagrams were developed to diagnose, treat, and follow up all forms of primary or recurrent GTD. The definitions and flow diagrams were drafted and adapted in consecutive (online) meetings until consensus was reached followed by an external review process. Here, the final guidelines are presented together with the available supporting evidence from the literature.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (52)
Christianne Lok
Department of Gynaecologic Oncology, Centre of Gynaecologic Oncology Amsterdam, Amsterdam, the Netherlands
Nienke van Trommel
Department of Gynaecologic Oncology, Centre of Gynaecologic Oncology Amsterdam, Amsterdam, the Netherlands
Elena Ioana Braicu
Department of Gynecology, Campus Virchow, Charité Universitätsmedizin Berlin and North Eastern German Society for Gynecologic Oncology (NOGGO), Berlin, Germany
Francois Planchamp
Institut Bergonié, Bordeaux, France
Ross Berkowitz
New England Trophoblastic Disease Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Michael Seckl
Department of Surgery & Cancer, Charing Cross Hospital Gestational Trophoblastic Disease Center, Charing Cross Hospital Campus of Imperial College London, London, United Kingdom
Inge O. Baas
Alice Bergamini
Department of Obstetrics and Gynecology, San Raffaele Hospital, Milan, Italy
Miguel Henriques Abreu
Department of Medical Oncology, Portuguese Institute of Oncology of Porto, Porto, Portugal
Pierre-Adrien Bolze
Genevieve Bouchard-Fortier
Princess Margaret Cancer Centre, Toronto, ON, Canada
Antonio Braga
Maria Stephanie Fay S. Cagayan
Antonio Casado
Min Chul Choi
John Coulter
Kevin Elias
Hind H. Elmalik
Andrea Garrett
Ehsan Ghorani
Department of Medical Oncology, Charing Cross Hospital, London, United Kingdom
Andrea Gmur
Frederic Goffin
Francois Golfier
Neil Horowitz
Ulrika Joneborg
Baljeet Kaur
Imperial College Healthcare National Health Service Trust, North West London Pathology
Philip Tonui Kipkirui
Jacob Korach
ISGO and Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel
Xin Lu
Izildinha Maesta
Giorgia Mangili
Department of Obstetrics and Gynecology, San Raffaele Hospital, Milan, Italy
Gloria Marquina
Jerome Massardier
Hextan Y.S. Ngan
Ray Osborne
Nelleke P.B. Ottevanger
Sinan Ozalp
Naveed Sarwar
Department of Medical Oncology, Charing Cross Hospital, London, United Kingdom
Paradan K. Sekharan
Franziska Siegenthaler
Olesya Solheim
Lone Sunde
Fred C.G.J. Sweep
Grzegorz Szewczyk
Manuela Undurraga
Matthew C. Winter
Eiko Yamamoto
Benoît You
Lyon University Hospital, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), Lyon University, Lyon, France
Emelie Wallin
Anneke Westermann
Yang Xiang
Ignacio Zapardiel